Drug Trials Snapshots: HERNEXEOS - HERNEXEOS (zongertinib)

https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-hernexeos HERNEXEOS is a prescription drug used to treat adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA-approved test, and who have received prior systemic therapy.